Puma Biotechnology Reports Second Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Puma Biotech (PBYI) Tops Q2 EPS, Revenues Miss
August 5, 2021 5:51 PM EDTPuma Biotech (NASDAQ: PBYI) reported Q2 EPS of $0.32, $0.34 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $48.9 million versus the consensus estimate of $51.6 million.
Net cash used in operating activities for the second quarter of 2021 was $0.1 million, compared to... More
